Antibodies to GAD and glycemic control in recent-onset IDDM

Diabetes Care

Volumn 20, Issue 12, 1997, Pages 1900-1903

  Hoeldtke, Robert D ^a   Bryner, Kimberly D ^a   Horvath, Gabriella G ^a   Byerly, Michele R ^a   Hobbs, Gerald R ^b   Marcovina, Santica M ^c   Lernmark, Ake ^c  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; GLYCOSYLATED HEMOGLOBIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DIABETES CONTROL; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIGAND BINDING; MALE; PANCREAS ISLET CELL; RADIOIMMUNOASSAY;

EID: 0030830832     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.12.1900     Document Type: Article

References (19)

1. Hagopian WA, Karlsen AE, Gottsater A, Landin-Olsson M, Grubin CE, Sundkvist G, PetersenJS, Boel E, Dyrberg T, Lernmark A: Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J Clin Invest 91:368-374, 1993
2. Petersen JS, Dyrberg T, Karlsen AE, Molvig J, Michelsen B, Nerup J, Mandrup-Poulsen T, the Canadian-European Randomized Control Trial Group: Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of β-cell function and remission in recent-onset IDDM after cyclosporin treatment: the Canadian-European Randomized Control Trial Group. Diabetes 43:1291-1296, 1994
3. Sundkvist G, Hagopian WA, Landin-Olsson M, Lernmark A, Ohlsson L, Ericsson C, AhlmenJ: Islet cell antibodies, but not glutamic acid decarboxylase antibodies, are decreased by plasmapheresis in patients with newly diagnosed insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 78:1159-1165, 1994
4. Marner B, Agner T, Binder C, Lernmark A, Nerup J, Mandrup-Poulsen T, Walldorff S: Increase reduction of fasting C peptide is associated with islet cell antibodies in type 1 (insulin dependent) diabetic patients. Diabetologia 28:875-880, 1985
5. Kaufman DL, Erlander MG, Clare-Saizler M, Atkinson MA, Maclaren NK, Tobin AJ: Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 89:283-292, 1992
6. Menard LA, Dempsey MD, Blankstein LA: Agar gel electrophoresis determination of glycosylated hemoglobin: effect of variant hemoglobins, hyperlipidemia, and temperature. Clin Chem 27:472, 1981
7. Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L, Karsen AE, Boel E, Michelsen B, Lernmark A: A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 37:344-350, 1994
8. Falorni A, Örtqvist E, Persson B, Lernmark A: Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 355 or 3H recombinant human ligands. J Immunol Methods 196:89-99, 1995
9. Bonifacio E, Lernmark A, Dawkins RL: Serum exchange and use of dilutions have improved precision of measurement of islet cell antibodies. J Immunol Methods 106:83-88, 1988
10. Schmidli RS, Colman PG, Bonifacio E, Bottazzo GF, Harrison LC: High level of concordance between assays for glutamic acid decarboxylase antibodies: the First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes 43:1005-1009, 1994
11. Schmidli RS, Colman PG, Bonifacio E: Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies: the Second International GADAb Workshop. Diabetes 44:636-640, 1995
12. Winer BJ: Multifactor experiments having repeated measures on the same elements. In Statistical Principles in Experimental Design. 2nd ed. New York, McGraw-Hill, 1979, p. 514-603
13. Gianani R, Rabin DU, Verge CF, Yu L, Babu SR, Pietropaolo M, Eisenbarth GS: ICA512 autoantibody radioassay. Diabetes 44:1340-1344, 1995
14. Vandewalle CL, Falorni A, Svanholm S, Lernmark A, Pipeleers DG, Gorus FK, Belgian Diabetes Registry: High diagnostic sensitivity of glutamate decarboxylase autoantibodies in IDDM with clinical onset between age 20 and 40 years. J Clin Endocrinol Metab 80:846-850, 1995
15. Tuomi T, Bjørses P, Falorni A, Partanen J, Perheentupa J, Lemmark A, Miettinen A: Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with APECED (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy). J Clin Endocrinol Metab 81:1488-1494, 1996
16. Batstra MR, Pina M, Quan J, Mulder P, DeBeaufort CE, Bruining GJ, Aanstoot HJ: Fluctuations in GAD65 antibodies after clinical diagnosis of IDDM in young children. Diabetes Care 20:642-644, 1997
17. Yokota I, Shirakawa N, Shima K, Matsuda J, Naito E, Ito M, Kuroda Y: Relationship between GAD antibody and residual β-cell function in children after overt onset of IDDM. Diabetes Care 19:74-75, 1996
18. Sabbah E, Kulmala P, Veijola R, Vahasalo P, Karjalainen J, Tuomilehto-Wolf E, Akerblom HK, Knip M, Childhood Diabetes in Finland Study Group: Glutamic acid decarboxylase antibodies in relation to other autoantibodies and genetic risk markers in children with newly diagnosed insulin-dependent diabetes. J Clin Endocrinol Metab 81:2455-2459, 1996.
19. Imagawa A, Itoh N, Waguri M, Miyagawa J, Yamamoto K, Nakajima H, Namba M, Hanafusa T, Matsuzawa Y: Immunohistological abnormalities in islets paralleled GAD antibodies and further deterioration of clinical features in recent-onset IDDM patients (Abstract). Diabetes 46 (Suppl. 1):7A, 1997